(NASDAQ: BBIO) Bridgebio Pharma's forecast annual revenue growth rate of 86.15% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 115.33%, and while it is forecast to beat the US market's average forecast revenue growth rate of 24.07%.
Bridgebio Pharma's revenue in 2026 is $353,780,000.On average, 22 Wall Street analysts forecast BBIO's revenue for 2026 to be $179,527,530,191, with the lowest BBIO revenue forecast at $142,585,250,739, and the highest BBIO revenue forecast at $250,714,165,713. On average, 19 Wall Street analysts forecast BBIO's revenue for 2027 to be $307,177,847,922, with the lowest BBIO revenue forecast at $223,542,223,080, and the highest BBIO revenue forecast at $363,256,112,505.
In 2028, BBIO is forecast to generate $441,110,472,957 in revenue, with the lowest revenue forecast at $347,839,407,465 and the highest revenue forecast at $598,746,281,991.